Prospective vaccines for this disease in clinical trials include ones named V180 and TV-003. prM and E proteins expressed by agents that cause this disease are targeted by the CYD-TDV vaccine. Low platelet count and NS1 antigens are detected in this disease’s febrile phase. (-5[1])Infection by one of four serotypes of an agent that (15[1])causes this disease in hosts vaccinated against it often leads to (-5[1])stronger symptoms (15[1])due to (15[1])(*) antibody-dependent (10[2])enhancement. (10[1])Extreme joint pain experienced (10[1]-5[1])during (10[1])this flaviviral (10[1])disease (10[1])led it to be (-5[1])nicknamed “breakbone (10[2])fever.” (10[3]-5[1])Chikungunya, (10[1]-5[1])Zika, and this (-5[2])disease are the most prevalent (10[1]-5[1])diseases (-5[1])spread by (-5[1])the (-5[2])Aedes (10[1]-5[3])aegypti (10[2]-5[2])(“AY-deez ay-JIP-tye”) mosquito (-5[2])vector. (-5[1])For 10 points, name (-5[1])this disease whose (-5[1])“severe” form was once called a namesake hemorrhagic fever. ■END■ (10[6]0[21])